The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial
Open accessAbstract
Importance: The effect of glucocorticoids on major kidney outcomes and adverse events in IgA nephropathy has been uncertain. Objective: To evaluate the efficacy and adverse effects of methylprednisolone in patients with IgA nephropathy at high risk of kidney function decline. Design, Setting, and Participants: An international, multicenter, double-blind, randomized clinical trial that enrolled 503 participants with IgA nephropathy, proteinuria greater than or equal to 1 g per day, and estimated glomerular filtration rate (eGFR) of 20 to 120 mL/min/1.73 m2 after at least 3 months of optimized background care from 67 centers in Australia, Canada, China, India, and Malaysia between May 2012 and November 2019, with follow-up until June 2021. Interventions: Participants were randomized in a 1:1 ratio to receive oral methylprednisolone (initially 0.6-0.8 mg/kg/d, maximum 48 mg/d, weaning by 8 mg/d/mo; n = 136) or placebo (n = 126). After 262 participants were randomized, an excess of serious infections was identified, leading to dose reduction (0.4 mg/kg/d, maximum 32 mg/d, weaning by 4 mg/d/mo) and addition of antibiotic prophylaxis for pneumocystis pneumonia for subsequent participants (121 in the oral methylprednisolone group and 120 in the placebo group). Main Outcomes And Measures: The primary end point was a composite of 40% decline in eGFR, kidney failure (dialysis, transplant), or death due to kidney disease. There were 11 secondary outcomes, including kidney failure. Results: Among 503 randomized patients (mean age, 38 years; 198 [39%] women; mean eGFR, 61.5 mL/min/1.73 m2; mean proteinuria, 2.46 g/d), 493 (98%) completed the trial. Over a mean of 4.2 years of follow-up, the primary outcome occurred in 74 participants (28.8%) in the methylprednisolone group compared with 106 (43.1%) in the placebo group (hazard ratio [HR], 0.53 [95% CI, 0.39-0.72]; P < .001; absolute annual event rate difference, -4.8% per year [95% CI, -8.0% to -1.6%]). The effect on the primary outcome was seen across each dose compared with the relevant participants in the placebo group recruited to each regimen (P for heterogeneity = .11): full-dose HR, 0.58 (95% CI, 0.41-0.81); reduced-dose HR, 0.27 (95% CI, 0.11-0.65). Of the 11 prespecified secondary end points, 9 showed significant differences in favor of the intervention, including kidney failure (50 [19.5%] vs 67 [27.2%]; HR, 0.59 [95% CI, 0.40-0.87]; P = .008; annual event rate difference, -2.9% per year [95% CI, -5.4% to -0.3%]). Serious adverse events were more frequent with methylprednisolone vs placebo (28 [10.9%] vs 7 [2.8%] patients with serious adverse events), primarily with full-dose therapy compared with its matching placebo (22 [16.2%] vs 4 [3.2%]). Conclusions and Relevance: Among patients with IgA nephropathy at high risk of progression, treatment with oral methylprednisolone for 6 to 9 months, compared with placebo, significantly reduced the risk of the composite outcome of kidney function decline, kidney failure, or death due to kidney disease. However, the incidence of serious adverse events was increased with oral methylprednisolone, mainly with high-dose therapy. Trial Registration: ClinicalTrials.gov Identifier: NCT01560052.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationWyatt, R. J., & Julian, B. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206793 · Cited by 1,222
Trimarchi, H., Barratt, J., Cattran, D. C., Cook, H. T., Coppo, R., Haas, M., Liu, Z.-H., Roberts, I. S. D., Yuzawa, Y., Zhang, H., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.02.003 · Cited by 1,192
Self-citationThe Pathophysiology of IgA Nephropathy
Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A. B., Renfrow, M. B., Wyatt, R. J., Scolari, F., Mestecky, J., Gharavi, A. G., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011050464 · Cited by 910
The incidence of primary glomerulonephritis worldwide: a systematic review of the literature
McGrogan, A., Franssen, C. F. M., & de Vries, C. S. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq665 · Cited by 741
Intensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Self-citationLv, J., Zhang, H., Wong, M. G., Jardine, M. J., Hladunewich, M., Jha, V., Monaghan, H., Zhao, M., Barbour, S., Reich, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.9362 · Cited by 540
Self-citationFellström, B. C., Barratt, J., Cook, H., Coppo, R., Feehally, J., de Fijter, J. W., Floege, J., Hetzel, G., Jardine, A. G., Locatelli, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30550-0 · Cited by 414
Self-citationIgA Nephropathy: Core Curriculum 2021
Pattrapornpisut, P., Avila-Casado, C., & Reich, H. N. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.01.024 · Cited by 343
Self-citationCurrent Understanding of the Role of Complement in IgA Nephropathy
Maillard, N., Wyatt, R. J., Julian, B. A., Kiryluk, K., Gharavi, A., Fremeaux-Bacchi, V., & Novak, J. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014101000 · Cited by 338
Cited by
Long-Term Outcomes in IgA Nephropathy
Pitcher, D., Braddon, F., Hendry, B., Mercer, A., Osmaston, K., Saleem, M. A., Steenkamp, R., Wong, K., Turner, A. N., Wang, K., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000135 · Cited by 458
Lafayette, R., Kristensen, J., Stone, A., Floege, J., Tesař, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Reich, H. N., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01554-4 · Cited by 337
Self-citationRovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D.-W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02302-4 · Cited by 307
Self-citationA Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
Mathur, M., Barratt, J., Chacko, B., Chan, T. M., Kooienga, L., Oh, K.-H., Sahay, M., Suzuki, Y., Wong, M. G., Yarbrough, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305635 · Cited by 239
Self-citationThe pathogenesis of IgA nephropathy and implications for treatment
Cheung, C. K., Alexander, S., Reich, H. N., Selvaskandan, H., Zhang, H., & Barratt, J. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00885-3 · Cited by 222
Self-citation
Metadata
- Authors
- Lv, J., Wong, M. G., Hladunewich, M. A., Jha, V., Hooi, L. S., Monaghan, H., Zhao, M., Barbour, S., Jardine, M. J., Reich, H. N., Cattran, D., Glassock, R., Levin, A., Wheeler, D. C., Woodward, M., Billot, L., Stepien, S., Rogers, K., Chan, T. M., Liu, Z.-H., Johnson, D. W., Cass, A., Feehally, J., Floege, J., Remuzzi, G., Wu, Y., Agarwal, R., Zhang, H., Perkovic, V., TESTING Study Group, Razavian, M., Gallagher, M., Daley, F., Hand, S., Knight, H., Gallagher, S., Bose, B., Lawlor, C., McCourt, J., Peh, C. A., Scott, E., Carroll, R., Coates, T., Hockley, B., Hockley, M., Latte, J., Nicholls, K., Cai, M., Champion de Crespigny, P., Cronin, T., Farrell, M., Hughes, P., Masterson, R., Sepe, G., Tan, S.-J., Toussaint, N., Wollstencroft, R., Cooper, B., Chang, M., Clayton, H., Tan, S., Tsang, H., Sudak, J., Laurin, L. P., Pichette, V., Chausse, K., Comeau, M., Lepine, L., Soliel, M., Beauchemin, S., René, E., Quach, M., Daoust, K., Lessard, A., Bachand-Fournier, M., Bétournay, M., Paradis, M.-S., Mikye Castor, M., Huang, S., Moist, L., Gallo, K., VanWesenbeeck, R., Longfield, T., Norris, F., Moyer, A., Bailey Lozon, Z., Miller, M., Clase, C., Rabbat, C., Salisbury, M., Mazzetti Vieira, A., Lalji, F., Moreau, C., Pannu, N., Hildebrand, A., Ruholl, N., Ahmad, N., Muneer, M., Girard, L., Mann, M. C., Hemmelgarn, B., Manns, B., Ravani, P., Li, S., Mackay, J., Gulewich, S., Sheriff, Z., Ferera, J., Vela, K., Gonzalez, A., Bhasin, A., Lam, P., Haji, F., Shi, S., Liu, L., Bao, Y., Sui, G., Wang, C., Li, Z., Lv, L., Yang, L., Li, H., Liu, Z., Zhang, J., Huang, B., Yang, Y., Fu, S., Li, S., Pei, H., Zhang, L., Lu, N., Xu, J., Xu, L., Yang, Q., Jin, J., Chen, N., Wang, W., Xu, L., Xia, Z., Xu, H., Huang, W., Mo, Y., Chen, W., Wang, L., Li, R., Yao, S., Li, X., Ni, Z., Wang, L., Gu, L., Pang, H., Zhou, Y., Jin, Y., Zhang, H., Wang, X., Le, W., Hou, J., Song, X., Zhu, L., Zhao, J., Hou, W., Wu, J., Shi, Y., Liu, J., Zhang, C., Wan, C., Chen, S., Zhu, H., Tang, F., Li, H., Jiang, X., Wang, M., Zuo, L., Yan, Y., Dong, B., Wang, Y., Zhang, X., Bai, L., Li, P., Qi, D., Cai, Z., Li, G., Wang, L., Peng, K., Hong, D., Yao, D., Jiang, A., Luo, Q., Hou, S., Zhang, F., Zheng, L., Luo, Y., Cai, G., Duan, S., Zhang, Y., Liang, S., Shao, X., Wang, R., Liu, X., Xu, Y., Zhang, J., Chen, J., Cheng, J., Zhao, L., Du, X., Chen, H., Zhu, B., Pan, W., Ma, Y., Cui, C., Zhang, Q., Zhang, J., Fu, P., Tang, X., Qin, W., Liang, Y., Li, D., Sun, G., Su, X., Zhao, B., He, Q., Shen, X., Zheng, D., Sun, Y., Zheng, H., Zheng, W., Lu, F., Lai, L., Zhang, M., Xu, N., Shi, H., Chen, W., Liang, X., Ye, Z., Xu, L., Zhang, R., Tao, Y., Xu, D., Tang, L., Lian, X., Ding, G., Wang, H., Yang, L., Li, Z., Hu, Z., Jiang, B., Guo, Z., Chang, J., Wang, Q., Li, N., Zhang, A., Shi, S., Li, Z., Xu, H., Bao, B., Zhao, Y., Nie, Z., Liu, T., Wang, Y., Cui, Z., Su, C., Gong, L., Liu, G., Yu, L., Wang, B., Xu, D., Li, Y., Lin, Q., Yu, K., Shen, Y., Cheng, H., Xu, X., Wang, Y., Liu, R., Xu, G., Han, M., Wang, L., Xing, C., Zhang, C., Huang, Z., Yang, G., Xu, X., Lv, X., Hong, H., Liu, B., Tao, L., Zhang, X., Yang, H., Yang, X., Zhang, X., Yang, H., Mao, Y., Wu, H., Li, T., Wang, H., Zhao, B., Lin, H., Yang, N., Fung, K. S., Chan, R., Law, R., Melemadathil, S., PT, H., Razak, R., Sinta, K. C., Natarajan, G., Mohammed, J., Thanigachalam, D. K., Devaraju, S. R., Alavala, S. R., Golla, A., Nagalla, V., Nallagasu, R., Sahay, M., Borra, S., Sahay, R., Dasyam, L. K. S., Kumbagiri, M., MSLN, P., Nazneen, A., Prathyusha, K., Ramachandran, R., Gupta, K. L., Sain, T., Prasad, N., Bhaduria, D. S., Pandy, A. K., Singh, P., Abdul Wahab, M. Z., Che Rohani, Z., Mohd Yassim, H., Razali, S. N. O., Saaidi, N., Wan Hazlina, W. M., Yahya, R., Yee, S. Y., Zaynah, N., Azahar, N. H., Tan, H. F., Loh, C. L., Hashim, S., Lee, Y. Y., Lim, X. J., Mohd Khairi, N., Ramanaidu, S., Thong, K. M., Liu, W. J., Ee, L. W., Mohd Yusoff, Y., Ngu, L. L. S., Chai, N. S., Hii, L. W. S., Tan, C. H. H., Wan Japar, S. H., Mushahar, L., Md Yusuff, S. H., Noor, M., Ng, K. P., Lim, S. K., Razali, W. A. F. A., Wan Md Adnan, W. A. H., Jayne, D., Greene, T., Walsh, M., Wang, A. Y.-M., Mather, A., & Wang, A. Y.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2022-05-17
- Volume
- 327
- Issue
- 19
- Pages
- 1888
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4280506915
- Cited by
- 354
- References
- 21
- FWCI
- 37.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2022.5368
- The paper
- Lv, J., Wong, M. G., Hladunewich, M. A., Jha, V., Hooi, L. S., Monaghan, H., Zhao, M., Barbour, S., Jardine, M. J., Reich, H. N., Cattran, D., Glassock, R., Levin, A., Wheeler, D. C., Woodward, M., Billot, L., Stepien, S., Rogers, K., Chan, T. M., . . . Wang, A. Y. (2022). Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2022.5368
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.